论文部分内容阅读
三十年来发现静注催产素引产安全有效,过去十年中进行的各种研究证明口服前列腺素E_2(PGE_2)引产同样有效。最近有报告口含催产素衍生物(demoxytocin去氨基催产素,简称DMO)引产和静注催产素效果相同。本文对两种口服催产药PGE_2片(Prostine)和去氨甲基催产素肠溶片(Sandopart)用于有无先行破膜时引产的效果及安全性进行了前瞻性及随机性研究。研究对象为Odense大学医院24个月内为引产而住院的523例病人,条件为住院时未临产、胎膜完整、单胎头位、胎儿存活。用Bishop宫颈评分
For more than 30 years, it has been found that intravenous oxytocin is safe and effective. Various studies conducted over the past decade have shown that oral administration of prostaglandin E_2 (PGE_2) is equally effective. Recent reports of oral oxytocin derivatives (demoxytocin deamino oxytocin, referred to as DMO) induction of labor and intravenous oxytocin effect the same. In this paper, we prospectively and stochasticly studied the efficacy and safety of two oral oxytocin drugs, Prostine and Sandopart, in the presence or absence of rupture of membranes. Subjects were hospitalized at Odense University Hospital for induction of labor within 24 months of 523 patients on condition that no hospitalization during labor, complete fetal membranes, single head position, fetal survival. Use Bishop cervical score